Evidence map›Paper›PMID 40067117›Full record

ArticleBlood2025

Clonal hematopoiesis landscape in frequent blood donors.

Darja Karpova, Hector Huerga Encabo, Elisa Donato, Silvia Calderazzo, Michael Scherer, Miriam Llorian-Sopena, Aino-Maija Leppä, Roberto Würth, Patrick Stelmach, Despoina Papazoglou and 17 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Epigenetic alterations in Myeloid Malignancies.Advances in experimental medicine and biology · 2026
    Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Darja KarpovaDivision of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.
Hector Huerga EncaboHematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-3723-8624
Elisa DonatoDivision of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0003-3541-9170
Silvia CalderazzoDivision of Biostatistics, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0003-3106-9089
Michael SchererComputational Biology and Health Genomics, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0001-7990-6179
Miriam Llorian-SopenaBioinformatics and Biostatistics, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-2582-6602
Aino-Maija LeppäDivision of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0003-0849-1759
Roberto WürthDivision of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-8156-6756
Patrick StelmachDivision of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.
Despoina PapazoglouHematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.
Alessandra FerrelliHematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0003-2308-1352
Steven NgoHematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.
Iuliia KotovaEuropean Molecular Biology Laboratory, Hamburg, Germany.ORCID 0000-0001-8675-3043
Sabine HarenkampInstitute for Transfusion Medicine and Immunohematology, Goethe University Hospital Medical School, German Red Cross Blood Donor Service, Frankfurt, Germany.
Kai ZimmerDepartment of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-1357-8712
Dominik WolfDepartment of Internal Medicine V, Hematology and Oncology, Comprehensive Cancer Center Innsbruck, Medical University of Innsbruck, Innsbruck, Austria.
Jasper PantenDivision of Regulatory Genomics and Cancer Evolution, German Cancer Research Center, Heidelberg, Germany.
John ReedDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Adriana PrzybyllaDivision of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.
Torsten TonnInstitute for Transfusion Medicine and Immunohematology, Goethe University Hospital Medical School, German Red Cross Blood Donor Service, Frankfurt, Germany.
Annette Kopp-SchneiderDivision of Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Lars VeltenComputational Biology and Health Genomics, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.ORCID 0000-0002-1233-5874
John F DiPersioDivision of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
Terrence N WongDivision of Cancer Biology, Department of Medicine, University of Michigan Medical School, Ann Arbor, MI.
Dominique BonnetHematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom.ORCID 0000-0002-4735-5226
Halvard BonigInstitute for Transfusion Medicine and Immunohematology, Goethe University Hospital Medical School, German Red Cross Blood Donor Service, Frankfurt, Germany.ORCID 0000-0003-0088-2675
Andreas TrumppDivision of Stem Cells and Cancer, German Cancer Research Center, Heidelberg, Germany.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Cancer Research UK CC2027NCI NIH HHS P30 CA091842Wellcome Trust
6 · The paper itself

Abstract

abstractDonor blood saves lives, yet the potential impact of recurrent large-volume phlebotomy on donor health and hematopoietic stem cells (HSCs) remains largely unexplored. In our study, we conducted a comprehensive screening of 217 older male volunteer donors with a history of extensive blood donation (>100 lifetime donations) to investigate the phenomenon of clonal hematopoiesis (CH). No significant difference in the overall incidence of CH was found in frequent donors (FDs) compared with sporadic donors (<10 lifetime donations; 212 donors). However, upon deeper analysis of mutations in DNMT3A, the most commonly affected gene in CH, we observed distinct mutational patterns between the FD and age/sex-matched control donor cohorts. Functional analysis of FD-enriched DNMT3A variants examined in CRISPR-edited human HSCs demonstrated their competitive outgrowth potential upon stimulation with erythropoietin (EPO), a hormone that increases in response to blood loss. In contrast, clones harboring leukemogenic DNMT3A R882 mutations increase upon stimulation with interferon gamma. Through concurrent mutational and immunophenotypic profiling of primary samples at single-cell resolution, a myeloid bias of premalignant R882 mutant HSCs was found, whereas no significant lineage bias was observed in HSCs harboring EPO-responsive DNMT3A variants. The latter exhibited preferential erythroid differentiation when persistent erythropoietic stress was applied to CRISPR-edited human HSC xenografts. Our data demonstrate a nuanced, ongoing Darwinian evolution at the somatic stem cell level, with EPO identified as a novel environmental factor that favors HSCs carrying certain DNMT3A mutations.

Indexed as

Blood DonorsClonal HematopoiesisHematopoietic Stem CellsAdultAgedDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3AErythropoietinHumansMaleMiddle AgedMutationDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanErythropoietin

Identifiers

PMID40067117
PMCPMC7617549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.